Walvax Biotech Forecasts 9%-22% Decline in 2025 Non-GAAP Net Profit; Qilu Pharmaceutical and Lisata Therapeutics Terminate Collaboration
Walvax
Human Vaccine Research and Development, Manufacturer
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
Allist Pharmaceuticals
Innovative Drug Developer
Hybio Pharmaceutical
Peptide Drug Developer
Innovent
High-end Biologics Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
Vaccine Companies Are Having a Hard Time.
On January 28, Walvax Biotechnology Co., Ltd. announced that the estimated revenue for the whole year of 2025 is 2.4 billion to 2.43 billion yuan; the non-net profit is 85 million to 99 million yuan, a year-on-year decrease of 9% to 22%.
Qilu Pharmaceutical's Pipeline Introduction Changes.
On January 27, Lisata Therapeutics announced that it had reached an agreement with Qilu Pharmaceutical, mutually agreeing to terminate the exclusive license and cooperation agreement signed in February 2021. This move means that Lisata has fully regained all development and commercialization rights for its core candidate drug, certepetide (formerly known as LSTA1), in Greater China from Qilu Pharmaceutical.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Capital Information
1) Allist Pharmaceuticals expects a 46% increase in revenue and a 50% increase in profit by 2025.
On January 28, Allist Pharmaceuticals released its 2025 earnings forecast, expecting total annual revenue to reach 5.2 billion yuan, an increase of approximately 1.642 billion yuan compared to the same period last year, representing a year-on-year growth of 46.15%. The net profit attributable to the parent company's shareholders for the entire year is expected to be 2.15 billion yuan, an increase of 720 million yuan compared to the same period last year, representing a year-on-year growth of 50.37%.
2) CanSino Expected to Achieve a Profit of 24.5-29 Million Yuan
On January 27, CanSino Biologics released its 2025 performance forecast, expecting to achieve annual operating revenue of RMB 1.040-1.080 billion, an increase of RMB 193.7-233.7 million compared with the same period last year, representing a year-on-year growth of 22.88%-27.61%. The net profit attributable to the parent company's owners is expected to be RMB 24.5-29 million for the full year.
3) Walvax's 2025 non-GAAP net profit is expected to decrease by 9%-22%
On January 28, Walvax Biotechnology Co., Ltd. announced that the estimated revenue for the whole year of 2025 is 2.4 billion to 2.43 billion yuan; the non-net profit is 85 million to 99 million yuan, a year-on-year decrease of 9%-22%.
4) Hybio Pharmaceutical forecasts a profit of 40 to 50 million yuan in 2025
On January 28, Hybio Pharmaceutical announced that it expects the net profit attributable to shareholders of the listed company in 2025 to be between RMB 40 million and RMB 50 million, compared to a loss of RMB 173.654 million in the same period last year.
/ 02 /
Pharmaceutical News
1) Innovent Bio's IBI3028 Receives Clinical Approval
On January 28, according to the CDE official website, Innovent Bio's IBI3028 received clinical approval for potential use in locally advanced, unresectable, or metastatic solid tumors that have failed standard treatment.
2) Novartis' Key Lipid-Lowering Drug Approved for New Indication
On January 28, Novartis announced that the new indication for inclisiran sodium injection was approved by the NMPA as an adjunct to diet, used alone for adult patients with primary hypercholesterolemia (non-familial) or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C).
3) Drug Farm ALPK1 Inhibitor Granted FDA Fast Track Designation
On January 28, Drug Farm announced that the U.S. FDA had granted Fast Track designation to its investigational ALPK1 inhibitor DF-003 for the treatment of ROSAH syndrome.
/ 04 /
Overseas Pharmaceutical News
1) Qilu Pharmaceutical and Lisata Terminate Cooperation
On January 27, Lisata Therapeutics announced that it had reached an agreement with Qilu Pharmaceutical, mutually agreeing to terminate the Exclusive License and Cooperation Agreement originally signed in February 2021. This move means that Lisata has fully regained all development and commercialization rights for its core candidate drug, certepetide (formerly known as LSTA1), in Greater China from Qilu Pharmaceutical.
PS: Welcome to scan the QR code below to add Amino Jun's WeChat for communication.
